Cytotoxic activity assessment and c-Src tyrosine kinase docking simulation of thieno[2,3-b] pyridine-based derivatives

Medicinal Chemistry Research

Volumn 23, Issue 3, 2014, Pages 1225-1233

  Nikkhoo, Ali Reza ^a,b,c   Miri, Ramin ^b,c   Arianpour, Nahid ^a   Firuzi, Omidreza ^b   Ebadi, Ahmad ^b,c   Salarian, Amir Ahmad ^a  

^a AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytotoxic activity; Docking simulation; Ligand efficiency; Thienopyridine

Indexed keywords

EID: 84893778085     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-013-0729-7     Document Type: Article

References (34)

1. Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10(7):464-469
2. Abdel-Rahman A, Bakhite E, Al-Taifi E (2003) Synthesis and antimicrobial testing of some new S-substituted-thiopyridines, thienopyridines, pyridothienopyrimidines and pyridothienotriazines. Pharmazie 58(6):372-377
3. Abreu R, Ferreira IC, Calhelha RC, Lima RT, Vasconcelos MH, Adega F, Chaves R, Queiroz M-JR (2011) Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno [3, 2-b] pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies. Eur J Med Chem 46(12):5800-5806
4. Atatreh N, Stojkoski C, Smith P, Booker GW, Dive C, Frenkel AD, Freeman S, Bryce RA (2008) In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand. Bioorg Med Chem Lett 18(3):1217-1222
5. Azizian J, Mohammadi MK, Firuzi O, Razzaghi-asl N, Miri R (2012) Synthesis, biological activity and docking study of some new isatin Schiff base derivatives. Med Chem Res 21(11):3730-3740
6. Azizmohammadi M, Khoobi M, Ramazani A, Emami S, Zarrin A, Firuzi O, Miri R, Shafiee A (2013) 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 59:15-22. doi: http://dx.doi.org/10.1016/j.ejmech.2012.10.044
7. Boschelli DH, Wu B, Barrios Sosa AC, Durutlic H, Ye F, Raifeld Y, Golas JM, Boschelli F (2004) Identification of 7-phenylaminothieno-[3, 2-b] pyridine-6-carbonitriles as a new class of Src kinase inhibitors. J Med Chem 47(27):6666-6668
8. Boschelli DH, Wu B, Barrios Sosa AC, Durutlic H, Chen JJ, Wang Y, Golas JM, Lucas J, Boschelli F (2005) Synthesis and Src kinase inhibitory activity of 2-phenyl-and 2-thienyl-7-phenylaminothieno [3, 2-b] pyridine-6-carbonitriles. J Med Chem 48(11):3891-3902
9. Guarino M (2010) Src signaling in cancer invasion. J Cell Physiol 223(1):14-26
10. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9(10):430
11. Huang H, Ma J, Shi J, Meng L, Jiang H, Ding J, Liu H (2010) Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase. Bioorg Med Chem 18(13):4615-4624
12. Lee K, Kim J, Jeong K-W, Lee KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y (2009) Structure-based virtual screening of Src kinase inhibitors. Bioorg Med Chem 17(8):3152-3161
13. Litvinov V, Dotsenko V, Krivokolysko S (2005) Thienopyridines: synthesis, properties, and biological activity. Russ Chem Bull 54(4):864-904
14. Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S (2012) 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. Eur J Med Chem 47:125-137
15. Miri R, Motamedi R, Rezaei MR, Firuzi O, Javidnia A, Shafiee A (2011) Design, synthesis and evaluation of cytotoxicity of novel chromeno [4, 3-b] quinoline derivatives. Arch Pharm (Weinheim) 344(2):111-118
16. Mitra SK, Schlaepfer DD (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18(5):516-523
17. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785-2791
18. Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S (2006) Evolution of the thienopyridine class of inhibitors of IκB kinase-β: part I: hit-to-lead strategies. J Med Chem 49(10):2898-2908
19. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1):55-63
20. Noronha G, Barrett K, Cao J, Dneprovskaia E, Fine R, Gong X, Gritzen C, Hood J, Kang X, Klebansky B (2006) Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett 16(21):5546-5550
21. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC (2003) Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 309(2):377-383
22. Penthala NR, Yerramreddy TR, Crooks PA (2010) Microwave assisted synthesis and in vitro cytotoxicities of substituted (Z)-2-amino-5-(1-benzyl-1H- indol-3-yl) methylene-1-methyl-1H-imidazol-4 (5H)-ones against human tumor cell lines. Bioorg Med Chem Lett 20(2):591-593
23. Pevet I, Brulé C, Tizot A, Gohier A, Cruzalegui F, Boutin JA, Goldstein S (2011) Synthesis and pharmacological evaluation of thieno [2, 3-b] pyridine derivatives as novel c-Src inhibitors. Bioorg Med Chem 19(8):2517-2528
24. Queiroz M-JR, Calhelha RC, Vale-Silva LA, Pinto E, Lima RT, Vasconcelos MH (2010) Efficient synthesis of 6-(hetero) arylthieno [3, 2- b] pyridines by Suzuki-Miyaura coupling. Evaluation of growth inhibition on human tumor cell lines, SARs and effects on the cell cycle. Eur J Med Chem 45(12):5628-5634
25. Saito K, Nakao A, Shinozuka T, Shimada K, Matsui S, Oizumi K, Yano K, Ohata K, Nakai D, Nagai Y, Naito S (2013) Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents. Bioorg Med Chem 21(7):1628-1642. doi: 10.1016/j.bmc.2013.01.071
26. Salarian AA, Asadi-Eskandar A, Sakhteman A, Abdi K (2012) Synthesis and docking studies of some 3-amino-6-(thiophen-2-yl)thieno[2, 3-b]pyridine derivatives. Asian J Chem 25(3):1275-1278
27. Schnute ME, Cudahy MM, Brideau RJ, Homa FL, Hopkins TA, Knechtel ML, Oien NL, Pitts TW, Poorman RA, Wathen MW (2005) 4-Oxo-4,7-dihydrothieno [2, 3-b] pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. J Med Chem 48(18):5794-5804
28. Shah YM, Rowan BG (2005) The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor α promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19(3):732-748
29. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D (2007) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4(1):42-50
30. Thaimattam R, Daga PR, Banerjee R, Iqbal J (2005) 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg Med Chem 13(15):4704-4712
31. Trujillo JI (2011) MEK inhibitors: a patent review 2008-2010. Expert Opin Ther Pat 21(7):1045-1069
32. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8(2):127-134
33. Youssefyeh RD, Brown RE, Wilson J, Shah U, Jones H, Loev B, Khandwala A, Leibowitz MJ, Sonnino-Goldman P (1984) Pyrido [3', 2': 4, 5] thieno [3, 2-d]-N-triazines: a new series of orally active antiallergic agents. J Med Chem 27(12):1639-1643
34. Zeng X-X, Zheng R-L, Zhou T, He H-Y, Liu J-Y, Zheng Y, Tong A-P, Xiang M-L, Song X-R, Yang S-Y (2010) Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: synthesis, preliminary structure-activity relationships, and in vitro biological evaluation. Bioorg Med Chem Lett 20(21):6282-6285